Could better tolerated HIV drug regimens improve patient outcome?

AIDS

Volumn 26, Issue 15, 2012, Pages 1953-1959

  Smit, Mikaela ^a   Smit, Colette ^b   Cremin, Ide ^a   Garnett, Geoffrey P ^a   Hallett, Timothy ^a   De Wolf, Frank ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b STICHTING HIV MONITORING   (Netherlands)

Author keywords

antiretroviral therapy; ATHENA; mathematical models; new drug regimens; toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NETHERLANDS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HIV-1; HUMANS; LONG-TERM CARE; MALE; MODELS, THEORETICAL; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; VIRAL LOAD;

EID: 84866738913     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835722bd     Document Type: Article

References (32)

1. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
2. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22:1951-1960.
3. Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita 2011; 47:44-48.
4. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730. (Pubitemid 28534954)
5. Lohse N, Hansen A-BE, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95. (Pubitemid 351640011)
6. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson A, Lambert P, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51-59. (Pubitemid 351920404)
7. Randell P, Moyle G. Antiretroviral therapy with heart. Am J Ther 2009; 16:579-584.
8. Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, et al. Drug-class-wide resistance to antiretrovirals in HIVinfected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006; 11:553-560. (Pubitemid 44277419)
9. Montessori V, Press N, Harris M, Akagi L, Montaner JSG. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004; 170:229-238. (Pubitemid 38134804)
10. Miron RE, Smith RJ. Modelling imperfect adherence to HIV induction therapy. BMC Infect Dis 2010; 10:6-6.
11. Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin Pharmacother 2011; 12:31-46.
12. Ananworanich J. Reaching undetectable viral loads after initial HIV treatment. Future HIV Therapy 2007; 1:81-89.
13. van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17:2227-2236. (Pubitemid 37338896)
14. CBS. Statistics Netherlands. http://www.cbs.nl/en-GB/menu/home/default. htm [Accessed 29 July 2012].
15. van Sighem A, Danner S, Ghani AC, Gras L, Anderson RM, de Wolf F. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr 2005; 40:212-218. (Pubitemid 41395721)
16. The Antiretroviral Therapy Cohort Collaboration. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38:1624-1633.
17. d' Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 2000; 14:499-507. (Pubitemid 30209692)
18. Yuan Y, L'italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006; 7:156-162. (Pubitemid 43337594)
19. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retrovir 2005; 21:743-752. (Pubitemid 41434178)
20. Sabundayo BP, McArthur JH, Langan SJ, Gallant JE, Margolick JB. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. Pharmacotherapy 2006; 26:674-681. (Pubitemid 43673049)
21. The HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123-137.
22. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343. doi:10.1136/bmj.d6016
23. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-868. (Pubitemid 29126872)
24. Ribera E, Paradineiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 2008; 9:407-417.
25. Bygrave H, Ford N, van Cutsem G, Hilderbrand K, Jouquet G, Goemaere E, et al. Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr 2011; 56:e75-e78.
26. Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, et al. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. J Acquir Immune Defic Syndr 2011; 58:e68-e74.
27. Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50%adherence to antiretroviral therapy. PLoS ONE 2009; 4:e7196.
28. Pujades-Rodríguez M, Balkan S, Arnould L, Brinkhof MAW, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 2010; 304:303-312.
29. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:65-72. (Pubitemid 46806622)
30. Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, MacArthur RD, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008; 22:75-82. (Pubitemid 350294880)
31. Ford N, Darder M, Spelman T, Maclean E, Mills E, Boulle A. early adherence to antiretroviral medication as a predictor of long-Term hiv virological suppression: five-year follow up of an observational cohort. PLoS One 2010; 5. doi:10.1371/journal. pone.0010460
32. Phillips, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-1451. (Pubitemid 351635534)